Flyband-peds: evaluating biomechanics of integrated exoskeleton footwear for pediatric charcot-marie-tooth disease

Active Grant Awarded

Award ID
R43HD121341
Recipient
Awarding agency
Obligated
$305,904

Award facts

Completion date 31% complete
Place of performance
Glastonbury, CT 06033, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services National Institutes of Health National Institute of Child Health and Human Development awarded Results Group, LLC a grant obligating $305,904 on August 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865), as Grant R43HD121341. The recipient will develop and test FLYBAND-PEDS, a motorless, thin-walled exoskeleton embedded within the construction layers of a high-top sneaker for children with Charcot-Marie-Tooth (CMT) disease. The Phase I effort tests pediatric prototypes in a decentralized gait study and conducts human-factors interviews with families who often have more than one member with CMT. The project aims to provide support comparable to an entry-level ankle-foot orthosis while being more comfortable and less intrusive to daily activity, with the goal of earlier intervention against maladaptive gait and the risk of missing growth milestones. Performance runs from August 1, 2026 through the ultimate completion date of July 31, 2027, with place of performance in Glastonbury, CT 06033, USA. The assistance type is grant.

Description

Abstract
Motive labs is developing a new pediatric brace known as flyband-peds that addresses the current 10-year GAP in the start of bracing treatment for children with charcot-marie-tooth (CMT) disease. CMT is a genetic disease, frequently impacting more than one member of a family. Losses in leg and foot strength lead to changes in walking, reducing daily activity and increasing risk of not meeting developmental growth targets. This cascade can lead to reduced resilience to CMT symptoms across the adult lifespan. Flyband-peds exoskeleton footwear enables earlier intervention, aiming to reduce maladaptive gait and the risk of not attaining growth milestones. We have developed working flyband-peds prototypes through a grant from the national institute for disability, independent living, and rehabilitation research (NIDILRR). In preliminary interviews, children with CMT report that braces can be uncomfortable, bulky, high cost, interfere with freedom of motion, and have a medical aesthetic that makes them feel different from their counterparts who do not wear braces. By embedding a thin- walled, no-motor exoskeleton within the construction layers of a high-top sneaker, we aim to provide comparable support to an entry-level ankle foot orthosis (AFO) while being significantly more comfortable, less intrusive to daily activity, and in a form factor that does not require children to look different than their counterparts. Our prototype shoe has been received with enthusiastic responses by children with CMT and healthcare specialists. In this phase I effort, we propose to test these pediatric prototypes in a decentralized gait study and conduct human-factors interviews with families who often have more than one family member with CMT. We are confident in our ability to produce and test these prototypes given our demonstrated success in building other footwear and exoskeleton systems. To execute our gait study, we have identified a contract partner with an extensively validated portable gait analysis system that enables US to recruit participants in a decentralized format, coordinating our data acquisition to coincide with CMT clinic days at massachusetts general hospital and other CMT centers of excellence. Our experience extracting actionable design insights from end-user interviews will ensure that our commercial-ready flyband-peds will meet the needs of american families. Gathering our primary endpoints of TOE clearance and gait speed will enable US to evaluate flyband-peds performance, establish its effect size, and design an appropriately powered future phase II clinical study. Because the exoskeleton is hidden within high-top shoes, our production strategy allows US to decrease costs by leveraging footwear manufacturing scale and supply chains. As a class 1 medical device, flyband-peds does not require a 510(K) and may be sold direct-to-consumer and also through reimbursement to ensure that families have broad accessibility which is critical for children who routinely outgrow their footwear and braces. In the long term, flyband-peds will present an accessible alternative to bracing, enabling earlier intervention in disease progression with the aim of reducing compensatory gait and maintaining resilience across the lifespan.

Quick answers

Who received award R43HD121341?

R43HD121341 was awarded to Results Group, LLC by National Institute of Child Health and Human Development (National Institutes of Health) on August 1, 2026.

How much is award R43HD121341 worth?

$305,904 has been obligated on R43HD121341.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award